<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>ARS Pharmaceuticals announces real-world evidence on neffy effectiveness — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">ARS Pharmaceuticals announces real-world evidence on neffy effectiveness</h2>
    <div class="badge">2025-09-09T12:11:06+00:00</div>
    <ul>
      <li>Elevate Your Investing Strategy: - Take advantage of TipRanks Premium at 50% off!</li>
<li>Nearly 90% of 545 patients experiencing anaphylaxis symptoms during oral food challenge and allergen immunotherapy were successfully treated with a single dose of neffy by a healthcare provider.</li>
<li>Meta-analyses report a similar proportion of patients, 88.9%, being successfully treated with a single dose of epinephrine intramuscular injection or auto-injector by a healthcare provider for food-induced anaphylaxis.</li>
<li>Try Now&gt;&gt; See Insiders’ Hot Stocks on TipRanks &gt;&gt; Read More on SPRY:</li>
<li>Importantly, these real-world data build upon previously published clinical evidence, including a prospective Phase 3 study assessing the efficacy of neffy for the treatment of oral food challenge-induced anaphylaxis sym</li>
<li>Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.</li>
<li>In that study, no patients required a second dose of neffy for treatment of the initial anaphylactic reaction.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=ARS%20Pharmaceuticals%20announces%20real-world%20evidence%20on%20neffy%20effectiveness%0A%E2%80%A2%20Elevate%20Your%20Investing%20Strategy%3A%20-%20Take%20advantage%20of%20TipRanks%20Premium%20at%2050%25%20off%21%0A%E2%80%A2%20Nearly%2090%25%20of%20545%20patients%20experiencing%20anaphylaxis%20symptoms%20during%20oral%20food%20challenge%20and%20allergen%20immunotherapy%20were%20successfully%20treated%20with%20a%20single%20dose%20of%20neffy%20by%20a%20healthcare%20provider.%0A%E2%80%A2%20Meta-analyses%20report%20a%20similar%20proportion%20of%20patients%2C%2088.9%25%2C%20being%20successfully%20treated%20with%20a%20single%20dose%20of%20epinephrine%20intramuscular%20injection%20or%20auto-injector%20by%20a%20healthcare%20provider%20for%20food-induced%20anaphylaxis.%0A%E2%80%A2%20Try%20Now%3E%3E%20See%20Insiders%E2%80%99%20Hot%20Stocks%20on%20TipRanks%20%3E%3E%20Read%20More%20on%20SPRY%3A%0A%E2%80%A2%20Importantly%2C%20these%20real-world%20data%20build%20upon%20previously%20published%20clinical%20evidence%2C%20including%20a%20prospective%20Phase%203%20study%20assessing%20the%20efficacy%20of%20neffy%20for%20the%20treatment%20of%20oral%20food%20challenge-induced%20anaphylaxis%20sym%0A%E2%80%A2%20Published%20first%20on%20TheFly%20%E2%80%93%20the%20ultimate%20source%20for%20real-time%2C%20market-moving%20breaking%20financial%20news.%0A%E2%80%A2%20In%20that%20study%2C%20no%20patients%20required%20a%20second%20dose%20of%20neffy%20for%20treatment%20of%20the%20initial%20anaphylactic%20reaction.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fars-pharmaceuticals-announces-real-world-evidence-on-neffy-effectiveness%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/ars-pharmaceuticals-announces-real-world-121106007.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>